Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
Insurance prior authorization assistance included
123: 20092013 [DOI] [PubMed] [Google Scholar] 112.de Heer J, Rasmussen C, Coy DH, et al
For patients with type 2 diabetes and Hashimoto's, options include: Semaglutide (Ozempic) : Once-weekly injection with robust efficacy for glycemic control, weight loss, and cardiovascular risk reduction Semaglutide (Rybelsus) : Oral daily tablet requiring careful timing with levothyroxine Dulaglutide (Trulicity) : Once-weekly injection with established cardiovascular benefits Liraglutide (Victoza) : Daily injection with cardiovascular risk reduction and extensive long-term safety data Tirzepatide (Mounjaro) : Once-weekly injection combining GLP-1 and GIP receptor agonism, showing superior efficacy in clinical trials For patients with obesity and Hashimoto's, FDA-approved options include: Semaglutide (Wegovy) : Once-weekly injection at higher doses than Ozempic Liraglutide (Saxenda) : Daily injection Tirzepatide (Zepbound) : Once-weekly injection with significant weight loss efficacy The presence of Hashimoto's thyroiditis does not inherently favor one GLP-1 medication over another
Most prescribers and compounding pharmacies do not recommend or supply this combination
US$ 25.31
US$ 21.18
US$ 29.36
US$ 22.33
US$ 25.15
